Novel design for a phase IIa placebo-controlled, double-blind randomized withdrawal study to evaluate the safety and efficacy of CNV1014802 in patients with trigeminal neuralgia

Convergence Pharmaceuticals' Novel Sodium Channel Blocker CNV1014802 Shows Excellent Efficacy and Safety in Groundbreaking Phase II Trigeminal Neuralgia Study

Bioportfolio, 16 Jun 2014

CAMBRIDGE England June 16 2014 PRNewswire Convergence Pharmaceuticals &160;"Convergence" or "the Company"Highlights of the data&1…